Capricor Therapeutics
CAPR
7 hedge funds and large institutions have $5.36M invested in Capricor Therapeutics in 2015 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.7% more ownership
Funds ownership: 0% → 4.7% (+4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadfin Capital
New York
|
+$6.09M |
| 2 |
Morgan Stanley
New York
|
+$249K |
| 3 |
Millennium Management
New York
|
+$160K |
| 4 |
Perceptive Advisors
New York
|
+$34.5K |
| 5 |
CFN
Cordasco Financial Network
Naples,
Florida
|
+$26.8K |
Top Sellers
CAPR Hedge Fund Activity: Q1 2015 in Review
7 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2015, worth a combined $5.36M.
Buyers outnumbered sellers: 7 funds opened new CAPR positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $6.09M.
- 7 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $5.36M of Capricor Therapeutics stock for Q1 2015.
- 7 funds opened new Capricor Therapeutics positions in Q1 2015 and 0 closed out, a net change of +7 holders.
- The largest Capricor Therapeutics buyer in Q1 2015 was Broadfin Capital, an estimated $6.09M added.
Based on aggregated 13F filings for Q1 2015.